Pharmaceuticals, Biotechnology & Life Sciences

Discover how Novo Nordisk’s partnership with Hims & Hers reshapes GLP‑1 sales, boosts revenue and strengthens its competitive edge in digital health.

Incyte’s Zynyz gains EU approval for advanced anal‑canal carcinoma, offering superior progression‑free survival and a high‑margin rare‑disease opportunity amid evolving value‑based reimbursement models.

CSL Limited wins Canada’s pandemic‑preparedness contract, securing millions of doses of a cutting‑edge cell‑based, adjuvanted influenza vaccine to bolster national health security.

Alnylam partners with Tenaya Biosciences to accelerate RNAi therapies for cardiovascular disease, targeting PCSK9 and other genes to lower LDL‑C and reduce atherosclerosis risk.

Fosun’s KAT6A/B inhibitor enters phase‑I trials, targeting solid tumours with a novel epigenetic mechanism and early safety data from China’s SDA approval.

Thermo Fisher’s quiet growth in Germany shows how its microscopes combine cost‑effective performance, bundled consumables and AI‑driven imaging to outpace rivals and meet strict EU regulations.

Merck KGaA’s Q1 2026 results show modest revenue gains amid generic pressure on Mavenclad, currency headwinds, and patent cliffs—yet the firm pivots to China and high‑barrier biologics for future growth.

Discover how Novo Nordisk’s new partnership with Hims & Hers could reshape obesity treatment, boost market reach, and raise regulatory and brand‑management questions.

Insmed’s latest moves—price target hike, 85 employee grants and a Duchenne study partnership—boost rare‑disease growth, cost control and payer alignment, positioning the company for future gains.

Grifols SA faces U.S. trade risks, Spanish regulatory scrutiny, patent cliffs, and volatility, yet explores biosimilars, M&A, and diagnostics to protect revenue and strengthen market access.